Our retrospective cohort of 600 HER2+ breast cancer cases in the neoadjuvant treatment setting confirmed pCR was associated with better survival irrespective of the patients’ clinical and pathological characteristics, and could be used to predict these patients’ prognosis. Here, ERBB2 is linked to breast carcinoma.